Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NR082 Gene Therapy for LHON Associated with ND4 Mutation
NCT04912843Phase 3Recruiting
- Sponsor
- Neurophth
- Start
- Jun 2021
- Primary completion
- Feb 2024
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of esonadogene mvoparvovec in Leber hereditary optic neuropathy (LHON) (2 arms), sponsored by Neurophth. Primary endpoints: Safety and tolerability of NR082 at different doses at 12 weeks, Safety after NR082 treatment at 6 weeks and 1 more. Started Jun 2021; status: recruiting.
02
Drugs
esonadogene mvoparvovec
03
Conditions
Leber hereditary optic neuropathy (LHON)
Beyond the preview
Go deeper on NCT04912843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04912843.